ADVERTISEMENT
3-Point Drop in AIMS Score Provides Clinically Meaningful Gains in TD
A decrease of 3 points on the Abnormal Involuntary Movement Scale (AIMS) score is the minimal clinically important difference (MCID) for treatment of tardive dyskinesia with deutetrabenazine, according to a poster presented at Psych Congress 2020.
“Findings suggest an AIMS score reduction of ~3 is associated with clinically meaningful improvement in tardive dyskinesia symptoms,” researchers wrote.
Researchers performed analyses to identify correlations between AIMS score decreases and treatment success measured by the Patient Global Impression of Change scale and the Clinical Global Impression of Change scale.
Deutetrabenazine Offers Long-Term Benefit for Severe TD
Based on the Patient Global Impression of Change scale, the suggested MCID was a reduction of 2.8 in AIMS score when MCID was defined as: the difference between patients treated with deutetrabenazine with minimal improvement and those treated with placebo who had no improvement or the difference between patients who demonstrated treatment improvement and those who did not, according to the poster abstract. The suggested MCID was a 2.6-point reduction in AIMS score when MCID was defined as the difference between patients who demonstrated treatment success and those who did not.
Based on the Clinical Global Impression of Change scale, the suggested MCID was a reduction of 2.6 points on the AIMS score when the MCID was the difference between patients treated with deutetrabenazine with minimal improvement and those treated with placebo who had no improvement; a reduction of 2.8 when MCID was the difference between patients who demonstrated treatment improvement and those who did not; and a reduction of 3.0 when MCID was the difference between patients who demonstrated treatment success and those who did not.
“Therefore,” researchers wrote, “the suggested MCID for deutetrabenazine is –3.”
Teva Pharmaceutical Industries sponsored the study.
—Jolynn Tumolo
Reference
